Of 23 558 people without pre-existing dementia, 4135 (17·6%) had an admission with delirium. 5 key findings →
Design: cohort Participants: 23,558 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Research
27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Frailty, comorbidities, and other age-related diseases were associated with a higher risk of dementia but did not account for the elevated dementia risk observed after severe infections. 3 key findings →
Design: cohort Participants: 449,223 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
67/100
The evidence base for treating a range of nonmotor symptoms in PD has grown substantially in recent years. 2 key findings →
Participants: 37 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The prediction of dementia in AD by SMI with subsequent amnestic MCI supports the model of a consecutive 3-stage clinical manifestation of AD from SMI via MCI to dementia. 2 key findings →
Design: cohort study Participants: 2,415 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
People who had recovered from COVID-19, including those no longer reporting symptoms, exhibited significant cognitive deficits versus controls when controlling for age, gender, education level, income, racial-ethnic group, pre-existing medical disorders, tiredness, depression and anxiety. 2 key findings →
Design: cross-sectional Participants: 192 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Traditional neuroimage analysis pipelines involve computationally intensive, time-consuming optimization steps, and thus, do not scale well to large cohort studies with thousands or tens of thousands of individuals. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The CSF AD profile was more common in patients with SCI (31 of 60 [52%]), naMCI (25 of 37 [68%]), and aMCI (56 of 71 [79%]) than in healthy controls (28 of 89 [31%]). 3 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Nondemented individuals exhibit a slow rate of whole-brain atrophy from early in adulthood with white-matter loss beginning in middle age; in older adults, the onset of dementia of the Alzheimer type is associated with a markedly accelerated atrophy rate. 2 key findings →
Design: cross-sectional Participants: 192 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
High concentrations of Abeta(1-40) but not Abeta(1-42) at baseline were associated with an increased risk of dementia. 5 key findings →
Design: cohort study Participants: 6,713 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
During mean follow-up of 2.1 (range 1.5-3.4) years, 146 incident cases of dementia were detected, of which 105 were Alzheimer's disease. 3 key findings →
Design: case-control study Participants: 6,870 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Multivariate logistic regression analyses were conducted after adjusting for age, sex, and educational status. 1 key finding →
Design: cohort study Participants: 1,969 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Over a median of 18 years, 1180 former soccer players (15.4%) and 3807 controls (16.5%) died. 1 key finding →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Our findings indicate that quantitative gait measures predict future risk of cognitive decline and dementia in initially non-demented older adults. 4 key findings →
Design: cohort study Participants: 427 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
We estimated the remaining lifetime risks of developing Alzheimer's disease (AD) and dementia from all causes, based on data from longitudinal population studies. 5 key findings →
Design: longitudinal study Participants: 198 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
SMI and EMCI with self-reported concerns were associated with the same risk of AD dementia, suggesting that pre-LMCI risk conditions should be extended to SMI with concerns. 5 key findings →
Design: cohort study Participants: 2,892 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
66/100
Our cohort of 1,958,191 people from UK general practices had a median age at baseline of 55 years (IQR 45-66) and a median follow-up of 9·1 years (IQR 6·3-12·6). 4 key findings →
Design: cohort study Participants: 1,958,191 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Previously published community- or population-based studies of brain aging and dementia with autopsy were restricted to a single sex, a single ethnic group, Roman Catholic clergy, or focused pathological assessments. 2 key findings →
Design: longitudinal study Participants: 221 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The development of MCI is associated with measurements of cognition and depression, racial and constitutional factors, and cerebrovascular disease. 5 key findings →
Design: longitudinal study Participants: 927 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
There is some evidence that multifaceted interventions in hospital reduce the number of falls and that use of hip protectors in care homes prevents hip fractures. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
We included 18740 patients (10 205 women [54.5%]; mean [SD] age, 78.2[7.4] years), of which 4271 (22.8%) received at least one prescription for an antidepressant. 5 key findings →
Design: cohort study Participants: 18,740 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
66/100
Despite remarkable progress in the biomarker field in recent years, local validation of plasma biomarkers of Alzheimer’s disease (AD) and dementia is still lacking in Latin America. 5 key findings →
Design: cohort study Participants: 49 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Comparing two nationally representative surveys of older Americans 12 years apart, researchers found the share of seniors with dementia fell substantially, from 11.6% in 2000 to 8.8% in 2012. 4 key findings →
Design: cross-sectional Participants: 21,057 Evidence: high
Full summary, score breakdown and related studies → Original source
Researchers re-ran the same detailed dementia survey in the same three parts of England twenty years apart. 4 key findings →
Design: cross-sectional Participants: 15,431 Evidence: high
Full summary, score breakdown and related studies → Original source
By pooling two long-running community studies from the same region of Pennsylvania, researchers compared dementia rates across people born in different decades, from the 1900s to the 1940s. Each successively younger birth cohort had a substantially lower risk of developing dementia at a given age, with the youngest group's risk about a quarter of the oldest group's. This adds US evidence, independent of Framingham, that generational health improvements are lowering dementia risk. 4 key findings →
Design: cohort Participants: 3,010 Evidence: high
Full summary, score breakdown and related studies → Original source
The mortality rates for the derivation cohort and validation cohort, respectively, were 8.9% and 8.2% in hospital, 10.7% and 10.4% at 30 days, and 32.9% and 30.5% at 1 year. 1 key finding →
Participants: 2,624 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →